Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Pillars Article: A 39-kDa Protein on Activated Helper T Cells Binds CD40 and Transduces the Signal for Cognate Activation of B Cells. Proc. Natl. Acad. Sci. 1992. 89: 6550-6554.

Noelle RJ, Roy M, Shepherd DM, Stamenkovico I, Ledbetter JA, Aruffo A.

J Immunol. 2016 Dec 1;197(11):4195-4199. No abstract available.

2.

Comparison of Strut Coverage at 6 Months by Optical Coherence Tomography With Everolimus-Eluting Stenting of Bare-Metal Stent Restenosis Versus Stenosis of Nonstented Atherosclerotic Narrowing (from the DESERT Study).

Picchi A, Musumeci G, Calabria P, Cresti A, Rescigno R, Aruffo A, Prati F, Limbruno U.

Am J Cardiol. 2015 May 15;115(10):1351-6. doi: 10.1016/j.amjcard.2015.02.042. Epub 2015 Feb 18.

PMID:
25772742
3.

Pillars article: long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996. 381: 434-438. 1996.

Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, Tucker-Burden C, Cho HR, Aruffo A, Hollenbaugh D, Linsley PS, Winn KJ, Pearson TC.

J Immunol. 2011 Mar 1;186(5):2693-7. No abstract available.

4.

Construction of immunoglobulin fusion proteins.

Hollenbaugh D, Aruffo A.

Curr Protoc Immunol. 2002 May;Chapter 10:Unit 10.19A. doi: 10.1002/0471142735.im1019as48.

PMID:
18432866
5.

Use of monoclonal antibodies for expression cloning.

Hollenbaugh D, Aruffo A, Jones B, Linsley P.

Curr Protoc Immunol. 2001 May;Chapter 10:Unit 10.18. doi: 10.1002/0471142735.im1018s31. Review.

PMID:
18432683
6.

Transient expression of proteins using COS cells.

Aruffo A.

Curr Protoc Neurosci. 2001 May;Chapter 4:Unit 4.7. doi: 10.1002/0471142301.ns0407s02.

PMID:
18428490
7.

Use of monoclonal antibodies for expression cloning.

Hollenbaugh D, Aruffo A, Jones B, Linsley P.

Curr Protoc Mol Biol. 2003 May;Chapter 6:Unit 6.11. doi: 10.1002/0471142727.mb0611s62.

PMID:
18265331
8.

Transient expression of proteins using COS cells.

Aruffo A.

Curr Protoc Mol Biol. 2002 Nov;Chapter 16:Unit 16.12. doi: 10.1002/0471142727.mb1612s60.

PMID:
18265298
9.

Anti-CD40 therapy extends renal allograft survival in rhesus macaques.

Pearson TC, Trambley J, Odom K, Anderson DC, Cowan S, Bray R, Lin A, Hollenbaugh D, Aruffo A, Siadak AW, Strobert E, Hennigar R, Larsen CP.

Transplantation. 2002 Oct 15;74(7):933-40.

PMID:
12394833
10.

Scavenger receptor cysteine-rich domains 9 and 11 of WC1 are receptors for the WC1 counter receptor.

Ahn JS, Konno A, Gebe JA, Aruffo A, Hamilton MJ, Park YH, Davis WC.

J Leukoc Biol. 2002 Aug;72(2):382-90.

PMID:
12149430
11.

Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease.

Aruffo A, Hollenbaugh D.

Curr Opin Immunol. 2001 Dec;13(6):683-6. Review.

PMID:
11677090
12.

Retinoic acid and vitamin E modulate expression and release of CD178 in carcinoma cells: consequences for induction of apoptosis in CD95-sensitive cells.

Salih HR, Starling GC, Knauff M, Llewellyn MB, Davis PM, Pitts WJ, Aruffo A, Kiener PA.

Exp Cell Res. 2001 Nov 1;270(2):248-58.

PMID:
11640888
13.

Tissue distribution of CD6 and CD6 ligand in cattle: expression of the CD6 ligand (CD166) in the autonomic nervous system of cattle and the human.

Konno A, Ahn JS, Kitamura H, Hamilton MJ, Gebe JA, Aruffo A, Davis WC.

J Leukoc Biol. 2001 Jun;69(6):944-50.

PMID:
11404380
14.

CD44 binds to the Shigella IpaB protein and participates in bacterial invasion of epithelial cells.

Skoudy A, Mounier J, Aruffo A, Ohayon H, Gounon P, Sansonetti P, Tran Van Nhieu G.

Cell Microbiol. 2000 Feb;2(1):19-33.

PMID:
11207560
15.

Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells.

Salih HR, Kosowski SG, Haluska VF, Starling GC, Loo DT, Lee F, Aruffo AA, Trail PA, Kiener PA.

J Immunol. 2000 Sep 1;165(5):2903-10.

16.

Cell surface receptors and their ligands: in vitro analysis of CD6-CD166 interactions.

Bowen MA, Aruffo AA, Bajorath J.

Proteins. 2000 Aug 15;40(3):420-8. Review.

PMID:
10861932
17.

Differential regulation of CD40-mediated human B cell responses by antibodies directed against different CD40 epitopes.

Sakata N, Hamelmann E, Siadak AW, Terada N, Gerwins P, Aruffo A, Johnson GL, Gelfand EW.

Cell Immunol. 2000 May 1;201(2):109-23.

PMID:
10831320
18.

CD5 is A potential selecting ligand for B-cell surface immunoglobulin: a possible role in maintenance and selective expansion of normal and malignant B cells.

Pospisil R, Silverman GJ, Marti GE, Aruffo A, Bowen MA, Mage RG.

Leuk Lymphoma. 2000 Jan;36(3-4):353-65.

PMID:
10674908
19.

Molecular cloning, genomic organization and cell-binding characteristics of mouse Spalpha.

Gebe JA, Llewellyn M, Hoggatt H, Aruffo A.

Immunology. 2000 Jan;99(1):78-86.

20.

Colocalization of basic fibroblast growth factor and CD44 isoforms containing the variably spliced exon v3 (CD44v3) in normal skin and in epidermal skin cancers.

Grimme HU, Termeer CC, Bennett KL, Weiss JM, Schöpf E, Aruffo A, Simon JC.

Br J Dermatol. 1999 Nov;141(5):824-32.

PMID:
10583162
21.

The pleckstrin homology domain of the Wiskott-Aldrich syndrome protein is involved in the organization of actin cytoskeleton.

Imai K, Nonoyama S, Miki H, Morio T, Fukami K, Zhu Q, Aruffo A, Ochs HD, Yata J, Takenawa T.

Clin Immunol. 1999 Aug;92(2):128-37.

PMID:
10444357
22.

Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis.

von Leoprechting A, van der Bruggen P, Pahl HL, Aruffo A, Simon JC.

Cancer Res. 1999 Mar 15;59(6):1287-94.

23.

CD44 is not an adhesive receptor for osteopontin.

Smith LL, Greenfield BW, Aruffo A, Giachelli CM.

J Cell Biochem. 1999 Apr 1;73(1):20-30.

PMID:
10088720
24.

Adhesion molecules, their receptors, and their regulation: analysis of CD6-activated leukocyte cell adhesion molecule (ALCAM/CD166) interactions.

Bowen MA, Aruffo A.

Transplant Proc. 1999 Feb-Mar;31(1-2):795-6. Review. No abstract available.

PMID:
10083342
25.

CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1.

Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, Aruffo AA, Kanner SB.

Mol Cell Biol. 1999 Apr;19(4):2903-12.

26.
27.

Characterization of the heparan sulfate and chondroitin sulfate assembly sites in CD44.

Greenfield B, Wang WC, Marquardt H, Piepkorn M, Wolff EA, Aruffo A, Bennett KL.

J Biol Chem. 1999 Jan 22;274(4):2511-7.

28.

The role of the CD40 pathway in alloantigen-induced hyporesponsiveness in vivo.

Niimi M, Pearson TC, Larsen CP, Alexander DZ, Hollenbaugh D, Aruffo A, Linsley PS, Thomas E, Campbell K, Fanslow WC, Geha RS, Morris PJ, Wood KJ.

J Immunol. 1998 Nov 15;161(10):5331-7.

29.

Mutations of the CD40 ligand gene and its effect on CD40 ligand expression in patients with X-linked hyper IgM syndrome.

Seyama K, Nonoyama S, Gangsaas I, Hollenbaugh D, Pabst HF, Aruffo A, Ochs HD.

Blood. 1998 Oct 1;92(7):2421-34.

30.

A role for CD5 in cognate interactions between T cells and B cells, and identification of a novel ligand for CD5.

Bikah G, Lynd FM, Aruffo AA, Ledbetter JA, Bondada S.

Int Immunol. 1998 Aug;10(8):1185-96.

PMID:
9723705
31.
32.
33.

Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade.

Elwood ET, Larsen CP, Cho HR, Corbascio M, Ritchie SC, Alexander DZ, Tucker-Burden C, Linsley PS, Aruffo A, Hollenbaugh D, Winn KJ, Pearson TC.

Transplantation. 1998 Jun 15;65(11):1422-8.

PMID:
9645796
34.

Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway.

Melero I, Bach N, Hellström KE, Aruffo A, Mittler RS, Chen L.

Eur J Immunol. 1998 Mar;28(3):1116-21.

35.

Analysis of the ligand binding site in Fas (CD95) by site-directed mutagenesis and comparison with TNFR and CD40.

Starling GC, Kiener PA, Aruffo A, Bajorath J.

Biochemistry. 1998 Mar 17;37(11):3723-6.

PMID:
9521690
36.

Diminished expression of CD40 ligand may contribute to the defective humoral immunity in patients with MHC class II deficiency.

Nonoyama S, Etzioni A, Toru H, Ruggerie DP, Lewis D, Pollack S, Aruffo A, Yata JI, Ochs HD.

Eur J Immunol. 1998 Feb;28(2):589-98.

37.

Identification of CD44 residues important for hyaluronan binding and delineation of the binding site.

Bajorath J, Greenfield B, Munro SB, Day AJ, Aruffo A.

J Biol Chem. 1998 Jan 2;273(1):338-43.

38.

Analysis of the tyrosine phosphorylation and calcium fluxing of human CD6 isoforms with different cytoplasmatic domains.

Kobarg J, Whitney GS, Palmer D, Aruffo A, Bowen MA.

Eur J Immunol. 1997 Nov;27(11):2971-80.

PMID:
9394826
39.

Chondroitin sulphate composition and structure in alternatively spliced CD44 fusion proteins.

Piepkorn M, Hovingh P, Bennett KL, Aruffo A, Linker A.

Biochem J. 1997 Oct 15;327 ( Pt 2):499-506.

40.

CD6-ligand interactions: a paradigm for SRCR domain function?

Aruffo A, Bowen MA, Patel DD, Haynes BF, Starling GC, Gebe JA, Bajorath J.

Immunol Today. 1997 Oct;18(10):498-504. Review.

PMID:
9357143
41.

Sulfated galactocerebrosides as potential antiinflammatory agents.

Marinier A, Martel A, Banville J, Bachand C, Remillard R, Lapointe P, Turmel B, Menard M, Harte WE Jr, Wright JJ, Todderud G, Tramposch KM, Bajorath J, Hollenbaugh D, Aruffo A.

J Med Chem. 1997 Sep 26;40(20):3234-47.

PMID:
9379443
42.

Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype.

Zhu Q, Watanabe C, Liu T, Hollenbaugh D, Blaese RM, Kanner SB, Aruffo A, Ochs HD.

Blood. 1997 Oct 1;90(7):2680-9.

43.

Deleted in colorectal carcinoma (DCC) binds heparin via its fifth fibronectin type III domain.

Bennett KL, Bradshaw J, Youngman T, Rodgers J, Greenfield B, Aruffo A, Linsley PS.

J Biol Chem. 1997 Oct 24;272(43):26940-6.

44.

BMS-190394, a selectin inhibitor, prevents rat cutaneous inflammatory reactions.

Todderud G, Nair X, Lee D, Alford J, Davern L, Stanley P, Bachand C, Lapointe P, Marinier A, Martel A, Menard M, Wright JJ, Bajorath J, Hollenbaugh D, Aruffo A, Tramposch KM.

J Pharmacol Exp Ther. 1997 Sep;282(3):1298-304.

45.

Mutational analysis of the CD6 ligand binding domain.

Skonier JE, Bodian DL, Emswiler J, Bowen MA, Aruffo A, Bajorath J.

Protein Eng. 1997 Aug;10(8):943-7.

PMID:
9415444
46.

Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice.

Clegg CH, Rulffes JT, Haugen HS, Hoggatt IH, Aruffo A, Durham SK, Farr AG, Hollenbaugh D.

Int Immunol. 1997 Aug;9(8):1111-22.

PMID:
9263008
47.

CD6 recognizes the neural adhesion molecule BEN.

Skonier JE, Bowen MA, Aruffo A, Bajorath J.

Protein Sci. 1997 Aug;6(8):1768-70.

48.

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.

Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, Brown TJ, Emswiler J, Raecho H, Larsen CP, Pearson TC, Ledbetter JA, Aruffo A, Mittler RS.

J Exp Med. 1997 Jul 7;186(1):47-55.

49.

Characterization of mouse ALCAM (CD166): the CD6-binding domain is conserved in different homologs and mediates cross-species binding.

Bowen MA, Bajorath J, D'Egidio M, Whitney GS, Palmer D, Kobarg J, Starling GC, Siadak AW, Aruffo A.

Eur J Immunol. 1997 Jun;27(6):1469-78.

PMID:
9209500
50.

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.

Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, Mittler RS, Chen L.

Nat Med. 1997 Jun;3(6):682-5.

PMID:
9176498

Supplemental Content

Loading ...
Support Center